All In Biotech

Drug Trial Radar · NCT05684965

XTX301 in Patients With Advanced Solid Tumors

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

358

Planned (sponsor's estimate)

Start

May 11, 2023

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Xilio Development, Inc.Industry
Sponsor type
Industry
First posted
Jan 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • XTX301Drug

    XTX301 monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs) (Part 1A only)Time frame: From the first dose of the study drug at Cycle 1 Day 1 up to next applicable cycle visit (Cycle 2 Day 1 or Cycle 3 Day 1). Approximately 21 to 42 days. Each cycle is 21 days.
  2. Incidence of treatment-emergent adverse events (TEAEs) and changes in clinical laboratory valuesTime frame: Up to 24 months
  3. Investigator-assessed objective response rate (ORR) per RECIST 1.1 (for all Phase 2 disease specific cohorts except CRPC/APMR-PC)Time frame: up to 24 months
  4. PSA50 response rate and Investigator-assessed ORR per RECIST 1.1 by CT/MRI for patients with measurable disease (for Phase 2 CRPC/APMR-PC cohort only)Time frame: up to 24 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • HealthPartners Frauenshuh Cancer center

    Saint Louis Park, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • The Gabrail Pharmacology Phase 1 Research Center

    Canton, Ohio · Recruiting

  • University Hospital Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • University of Pittsburgh Medical Center-Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Tranquil Clinical Research

    Webster, Texas · Completed

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Sheboygan Cancer & Blood Specialists

    Sheboygan, Wisconsin · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.